M2-Polarized tumor-associated macrophages are associated with poor prognoses resulting from accelerated lymphangiogenesis in lung adenocarcinoma

Clinics

Volumn 66, Issue 11, 2011, Pages 1879-1886

  Zhang, Bicheng ^a   Yao, Guoqing ^a   Zhang, Yafei ^a,b   Gao, Juan ^a   Yang, Bo ^a   Rao, Zhiguo ^a   Gao, Jianfei ^a  

^a WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Lung adenocarcinoma; Lymphangiogenesis; M2 polarized macrophages; Prognosis; Tumor associated macrophages

Indexed keywords

EID: 81555202006     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322011001100006     Document Type: Article

References (39)

1. Porta C, Subhra Kumar B, Larghi P, Rubino L, Mancino A, Sica A. Tumor promotion by tumor-associated macrophages. Adv Exp Med Biol. 2007;604:67-86, doi: 10.1007/978-0-387-69116-9_5.
2. Mantovani A. La mala educación of tumor-associated macrophages: diverse pathways and new players. Cancer Cell. 2010;17:111-2, doi: 10.1016/j.ccr.2010.01.019.
3. Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer. 2008;15:1069-74, doi:10.1677/ERC-08-0036.
4. Lee CH, Espinosa I, Vrijaldenhoven S, Subramanian S, Montgomery KD, Zhu S, et al. Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin Cancer Res. 2008;14:1423-30, doi:10.1158/1078-0432.CCR-07-1712.
5. Shieh YS, Hung YJ, Hsieh CB, Chen JS, Chou KC, Liu SY. Tumorassociated macrophage correlated with angiogenesis and progression of mucoepidermoid carcinoma of salivary glands. Ann Surg Oncol. 2009;16:751-60, doi:10.1245/s10434-008-0259-6.
6. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66:605-12, doi: 10.1158/0008-5472.CAN-05-4005.
7. Mosser DM. The many faces of macrophage activation. J Leukoc Biol. 2003;73:209-12, doi: 10.1189/jlb.0602325
8. Edwards JP, Zhang X, Frauwirth KA, Mosser DM. Biochemical and functional characterization of three activated macrophage populations. J Leukoc Biol. 2006;80:1298-307, doi: 10.1189/jlb.0406249.
9. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med. 1992;176:287-92, doi: 10.1084/jem.176.1.287.
10. Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3:23-35, doi: 10.1038/nri978.
11. Gratchev A, Kzhyshkowska J, Köthe K, Muller-Molinet I, Kannookadan S, Utikal J, et al. Mphi1 and Mphi2 can be re-polarized by Th2 or Th1 cytokines, respectively, and respond to exogenous danger signals. Immunobiology. 2006;211:473-86, doi: 10.1016/j.imbio.2006.05.017.
12. Mantovani A, Allavena P, Sica A. Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur J Cancer. 2004;40:1660-7, doi: 10.1016/j.ejca.2004.03.016.
13. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006;42:717-27, doi: 10.1016/j.ejca.2006.01.003.
14. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci. 2008;13:453-61, doi: 10.2741/2692.
15. Hagemann T, Wilson J, Burke F, Kulbe H, Li NF, Plüddemann A, et al. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol. 2006;176:5023-32.
16. Kawamura K, Komohara Y, Takaishi K, Katabuchi H, Takeya M. Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol Int. 2009;59:300-5, doi: 10.1111/j.1440-1827.2009.02369.x.
17. Komohara Y, Ohnishi K, Kuratsu J, Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol. 2008;216:15-24, doi: 10.1002/path.2370.
18. Niino D, Komohara Y, Murayama T, Aoki R, Kimura Y, Hashikawa K, et al. Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL). Pathol Int. 2010;60:278-83, doi: 10.1111/j.1440-1827.2010.02514.x.
19. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature. 2005;438:946-53, doi: 10.1038/nature 04480.
20. Birner P, Schindl M, Obermair A, Breitenecker G, Kowalski H, Oberhuber G. Lymphatic microvessel density as a novel prognostic factor in early-stage invasive cervical cancer. Int J Cancer. 2001;95:29-33, doi: 10.1002/1097-0215(20010120)95:1,29::AID-IJC1005.3.0.CO;2-W.
21. Kim HS, Sung W, Lee S, Chang SG, Park YK. Lymphatic vessel densities of lymph node-negative prostate adenocarcinoma in Korea. Pathol Res Pract. 2009;205:249-54, doi: 10.1016/j.prp.2008.10.005.
22. Renyi-Vamos F, Tovari J, Fillinger J, Timar J, Paku S, Kenessey I, et al. Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancer. Clin Cancer Res. 2005;11:7344-53, doi: 10.1158/1078-0432.CCR-05-1077.
23. Kadota K, Huang CL, Liu D, Ueno M, Kushida Y, Haba R, et al. The clinical significance of lymphangiogenesis and angiogenesis in non-small cell lung cancer patients. Eur J Cancer. 2008;44:1057-67, doi: 10.1016/j.ejca.2008.03.012.
24. Schoppmann SF, Birner P, Stöckl J, Kalt R, Ullrich R, Caucig C, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol. 2002;161:947-56, doi: 10.1016/S0002-9440(10)64255-1.
25. Schoppmann SF, Fenzl A, Nagy K, Unger S, Bayer G, Geleff S, et al. VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival. Surgery. 2006;139:839-46, doi: 10.1016/j.surg.2005.12.008.
26. Kahn HJ, Marks A. A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest. 2002;82:1255-7.
27. Anagnostou VK, Tiniakos DG, Fotinou M, Achimastos A, Syrigos KN. Multiplexed analysis of angiogenesis and lymphangiogenesis factors predicts outcome for non-small cell lung cancer patients. Virchows Arch. 2011;458:331-40, doi: 10.1007/s00428-010-1015-4.
28. Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev. 2003;8:223-246.
29. Huang M, Wang J, Lee P, Sharma S, Mao JT, Meissner H, et al. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res. 1995;55:3847-53.
30. Ito N, Nakamura H, Tanaka Y, Ohgi S. Lung carcinoma: analysis of T helper type 1 and 2 cells and T cytotoxic type 1 and 2 cells by intracellular cytokine detection with flow cytometry. Cancer. 1999;85:2359-67, doi: 10.1002/(SICI)1097-0142(19990601)85:11,2359::AID-CNCR10.3.0.CO;2-A.
31. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677-86, doi: 10.1016/j.it.2004.09.015.
32. Ohtaki Y, Ishii G, Nagai K, Ashimine S, Kuwata T, Hishida T, et al. Stromal macrophage expressing CD204 is associated with tumor aggressiveness in lung adenocarcinoma. J Thorac Oncol. 2010;5:1507-15, doi: 10.1097/JTO.0b013e3181eba692.
33. Umemura N, Saio M, Suwa T, Kitoh Y, Bai J, Nonaka K, et al. Tumorinfiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol. 2008;83:1136-44, doi: 10.1189/jlb.0907611.
34. Hasita H, Komohara Y, Okabe H, Ashimine S, Kuwata T, Hishida T, et al. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci. 2010;101:1913-9, doi: 10. 1111/j.1349-7006.2010.01614.x.
35. Niino D, Komohara Y, Murayama T, Aoki R, Kimura Y, Hashikawa K, et al. Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL). Pathol Int. 2010;60:278-83, doi: 10.1111/j.1440-1827.2010.02514.x.
36. Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P. Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1phenotype associated with extended survival. Eur Respir J. 2009;33:118-26, doi: 10.1183/09031936.00065708.
37. Ma J, Liu L, Che G, Yu N, Dai F, You Z. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer. 2010;10:112, doi: 10.1186/1471-2407-10-112.
38. Pepper MS. Lymphangiogenesis and tumor metastasis: myth or reality? Clin Cancer Res. 2001;7:462-8.
39. Zhang B, Wang J, Gao J, Guo Y, Chen X, Wang B, et al. Alternatively activated RAW264.7 macrophages enhance tumor lymphangiogenesis in mouse lung adenocarcinoma. J Cell Biochem. 2009;107:134-43, doi: 10.1002/jcb.22110.